YOKNEAM, Israel, Nov. 6, 2023 /PRNewswire/ -- InMode Ltd. (NASDAQ: INMD), a leading global provider of innovative medical technologies, today announced the participation at the following investor conferences and events in November and December:
Jefferies London Healthcare Conference
Presenters: Moshe Mizrahy, Chief Executive Officer and Chairman
Format: In-person fireside chat moderated by Matt Taylor, Senior Equity Analyst, and one-on-one meetings
Location: London, U.K.
When: Tuesday, Nov. 14 at 8:00 am GMT
A live webcast of the presentation can be accessed here.
Canaccord MTDF Investor Conference
Presenters: Yair Malca, Chief Financial Officer
Format: In-person one-on-one meetings
Location: New York, NY
When: Thursday, Nov. 16
Mizuho Medical Device and Healthcare Services Summit 2023
Presenters: Yair Malca, Chief Financial Officer
Format: In-person one-on-one meetings
Location: New York, NY
When: Wednesday, Dec. 6
About InMode
InMode is a leading global provider of innovative medical technologies. InMode develops, manufactures, and markets devices harnessing novel radiofrequency ("RF") technology. InMode strives to enable new emerging surgical procedures as well as improve existing treatments. InMode has leveraged its medically accepted minimally invasive RF technologies to offer a comprehensive line of products across several categories for plastic surgery, gynecology, dermatology, otolaryngology, and ophthalmology. For more information about InMode and its wide array of medical technologies, visit www.inmodemd.com.
Investor Relations Contact:
Miri Segal-Scharia
MS-IR LLC
This email address is being protected from spambots. You need JavaScript enabled to view it.
917-607-8654
Last Trade: | US$16.52 |
Daily Change: | -0.50 -2.94 |
Daily Volume: | 244,501 |
Market Cap: | US$1.260B |
September 04, 2024 August 06, 2024 July 31, 2024 |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORECompass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB